Changes in Ischemia-modified Albumin in Myocardial Toxicity Induced by Anthracycline and Docetaxel Chemotherapy

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2017 Aug 11

PMID 28796051

Citations 3

Authors

Xiao-Dong Luan

Kai-Hua Zhao

Hong Hou

Yan-Hong Gai

Qi-Tang Wang

Qiang Mu

Yue Wan

Affiliations

Soon will be listed here.

Abstract

This study aims to evaluate differences in myocardial toxicity induced by different chemotherapy regimens. Patients were divided into 2 groups: epirubicin (EPI) combined with cyclophosphamide (EC) group and docetaxel combined with cyclophosphamide (TC) group. Changes in electrocardiograph (ECG) and ischemia-modified albumin (IMA) were determined pre- and 1, 3, and 6 courses of postchemotherapy. After the first course of chemotherapy, there was no significant difference in ECG and abnormal IMA incidence rates between the TC groups and EC groups (P > .05). After the third course and at the end of the sixth course, ECG and abnormal IMA incidence rates in the EC group were significantly higher than in the TC group (P < .05). Besides, IMA values significantly increased with the increase in chemotherapy courses in the EC group; and the value of the postsixth course was significantly higher than in the pre- and postfirst and -third courses of chemotherapy. IMA value in the postsixth course in the TC group was significantly higher than that in the pre- and postfirst and -third courses of chemotherapy. In addition, IMA values at the postfirst and -third courses of chemotherapy in the EC group were significantly higher than in the TC group. Both EC and TC chemotherapy regimens were harmful to the myocardium, and the incidence rate of myocardial damage increased with the increase of cumulative dose. Besides, the degree of myocardial damage in EC group was significantly higher than in the TC group.

Citing Articles

Mesenchymal Stem Cells Target Gastric Cancer and Deliver Epirubicin Tunneling Nanotubes for Enhanced Chemotherapy.

Zhou Y, Li Y, Wang H, Sun H, Su J, Fan Y Curr Stem Cell Res Ther. 2024; 19(10):1402-1413.

PMID: 38173205 DOI: 10.2174/011574888X287102240101060146.

Ischemia-Modified Albumin: Origins and Clinical Implications.

Shevtsova A, Gordiienko I, Tkachenko V, Ushakova G Dis Markers. 2021; 2021:9945424.

PMID: 34336009 PMC: 8315882. DOI: 10.1155/2021/9945424.

Effects of Xinnaoning combined with trimetazidine on the levels of CK and its isoenzymes, AST, ALT and LDH in patients with myocardial ischemia.

Zhu T, Han Q, Zhang X, Hou Q Am J Transl Res. 2021; 13(4):2875-2882.

PMID: 34017451 PMC: 8129328.

References

Roy D, Quiles J, Gaze D, Collinson P, Kaski J, Baxter G . Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart. 2005; 92(1):113-4. PMC: 1861004. DOI: 10.1136/hrt.2004.049643. View

Palumbo I, Palumbo B, Fravolini M, Marcantonini M, Perrucci E, Latini M . Brain natriuretic peptide as a cardiac marker of transient radiotherapy-related damage in left-sided breast cancer patients: A prospective study. Breast. 2015; 25:45-50. DOI: 10.1016/j.breast.2015.10.004. View

Di Marco A, Gaetani M, SCARPINATO B . Adriamycin (NSC-123,127): a new antibiotic with antitumor activity. Cancer Chemother Rep. 1969; 53(1):33-7. View

Mehta M, Marwah S, Ghosh S, Shah H, Trivedi A, Haridas N . A synergistic role of ischemia modified albumin and high-sensitivity troponin T in the early diagnosis of acute coronary syndrome. J Family Med Prim Care. 2016; 4(4):570-5. PMC: 4776611. DOI: 10.4103/2249-4863.174295. View

Kocak C, Kocak F, Akcilar R, Isiklar O, Kocak H, Bayat Z . Molecular and biochemical evidence on the protective effects of embelin and carnosic acid in isoproterenol-induced acute myocardial injury in rats. Life Sci. 2016; 147:15-23. DOI: 10.1016/j.lfs.2016.01.038. View

Chargari C, Kirov K, Bollet M, Magne N, Vedrine L, Cremades S . Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment. Cancer Treat Rev. 2010; 37(4):321-30. DOI: 10.1016/j.ctrv.2010.08.007. View

Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, OReilly S . Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet. 2009; 373(9676):1681-92. PMC: 2687939. DOI: 10.1016/S0140-6736(09)60740-6. View

Steuter J, Bociek R, Loberiza F, Mathers D, Armitage J, Vose J . Utility of prechemotherapy evaluation of left ventricular function for patients with lymphoma. Clin Lymphoma Myeloma Leuk. 2014; 15(1):29-34. DOI: 10.1016/j.clml.2014.06.026. View

Hanna A, Janczura M, Cho E, Dulhunty A, Beard N . Multiple actions of the anthracycline daunorubicin on cardiac ryanodine receptors. Mol Pharmacol. 2011; 80(3):538-49. DOI: 10.1124/mol.111.073478. View

10.

Shalenkova M, Mukhametova E, Mikhailova Z . [The role of necrosis and inflammation markers in prognostication of acute coronary heart disease]. Klin Med (Mosk). 2015; 91(11):14-20. View

11.

Cao H, Wang Y, Wang Q, Wang R, Guo S, Zhao X . Taxol prevents myocardial ischemia-reperfusion injury by inducing JNK-mediated HO-1 expression. Pharm Biol. 2015; 54(3):555-60. DOI: 10.3109/13880209.2015.1060507. View

12.

Peacock F, Morris D, Anwaruddin S, Christenson R, Collinson P, Goodacre S . Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J. 2006; 152(2):253-62. DOI: 10.1016/j.ahj.2005.12.024. View

13.

Jekunen A, Heikkila P, Maiche A, Pyrhonen S . Paclitaxel-induced myocardial damage detected by electron microscopy. Lancet. 1994; 343(8899):727-8. DOI: 10.1016/s0140-6736(94)91603-9. View

14.

Roy D, Quiles J, Sharma R, Sinha M, Avanzas P, Gaze D . Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. Clin Chem. 2004; 50(9):1656-60. DOI: 10.1373/clinchem.2004.031690. View

15.

Sbarouni E, Georgiadou P, Voudris V . Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med. 2010; 49(2):177-84. DOI: 10.1515/CCLM.2011.037. View

16.

Abboud H, Labreuche J, Meseguer E, Lavallee P, Simon O, Olivot J . Ischemia-modified albumin in acute stroke. Cerebrovasc Dis. 2006; 23(2-3):216-20. DOI: 10.1159/000097644. View

17.

Zhang Y, Shi J, Li Y, Wei L . Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz). 2009; 57(6):435-45. PMC: 2809808. DOI: 10.1007/s00005-009-0051-8. View

18.

Mistiaen W . Cancer in heart disease patients: what are the limitations in the treatment strategy?. Future Cardiol. 2013; 9(4):535-47. DOI: 10.2217/fca.13.33. View

19.

Talwalkar S, Bon Homme M, Miller J, Elin R . Ischemia modified albumin, a marker of acute ischemic events: a pilot study. Ann Clin Lab Sci. 2008; 38(2):132-7. View

20.

Octavia Y, Tocchetti C, Gabrielson K, Janssens S, Crijns H, Moens A . Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012; 52(6):1213-25. DOI: 10.1016/j.yjmcc.2012.03.006. View